Display options
Cite
Perrin Ross A, Williamson A, Smrtka J, et al. Assessing relapse in multiple sclerosis questionnaire: results of a pilot study. Mult Scler Int. 2013;2013:470476doi: 10.1155/2013/470476.
Perrin Ross, A., Williamson, A., Smrtka, J., Flemming Tracy, T., Saunders, C., Easterling, C., Niewoehner, J., & Mutschler, N. (2013). Assessing relapse in multiple sclerosis questionnaire: results of a pilot study. Multiple sclerosis international, 2013470476. https://doi.org/10.1155/2013/470476
Perrin Ross, Amy, et al. "Assessing relapse in multiple sclerosis questionnaire: results of a pilot study." Multiple sclerosis international vol. 2013 (2013): 470476. doi: https://doi.org/10.1155/2013/470476
Perrin Ross A, Williamson A, Smrtka J, Flemming Tracy T, Saunders C, Easterling C, Niewoehner J, Mutschler N. Assessing relapse in multiple sclerosis questionnaire: results of a pilot study. Mult Scler Int. 2013;2013:470476. doi: 10.1155/2013/470476. Epub 2013 May 26. PMID: 23766909; PMCID: PMC3677606.
Copy Download .nbib Format: NLM
Share it on

Mult Scler Int. 2013;2013:470476. doi: 10.1155/2013/470476. Epub 2013 May 26.

Assessing relapse in multiple sclerosis questionnaire: results of a pilot study.

Multiple sclerosis international

Amy Perrin Ross, Alona Williamson, Jennifer Smrtka, Tracy Flemming Tracy, Carol Saunders, Constance Easterling, John Niewoehner, Nicole Mutschler

Affiliations

  1. Department of Neurosciences, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA.

PMID: 23766909 PMCID: PMC3677606 DOI: 10.1155/2013/470476

Abstract

There is need for a brief but comprehensive objective assessment tool to help clinicians evaluate relapse symptoms in patients with multiple sclerosis (MS) and their impact on daily functioning, as well as response to treatment. The 2-part Assessing Relapse in Multiple Sclerosis (ARMS) questionnaire was developed to achieve these aims. Part 1 consists of 7 questions that evaluate relapse symptoms, impact on activities of daily living (ADL), overall functioning, and response to treatment for previous relapses. Part 2 consists of 7 questions that evaluate treatment response in terms of symptom relief, functioning, and tolerability. The ARMS questionnaire has been evaluated in 103 patients with MS. The most commonly reported relapse symptoms were numbness/tingling (67%), fatigue (58%), and leg/foot weakness (55%). Over half of patients reported that ADL or overall functioning were affected very much (47%) or severely (11%) by relapses. Prescribed treatments for relapses included intravenous and/or oral corticosteroids (87%) and adrenocorticotropic hormone (13%). Nearly half of patients reported that their symptoms were very much (33%) or completely resolved (16%) following treatment. The most commonly reported adverse events were sleep disturbance (45%), mood changes (33%), weight gain (29%), and increased appetite (26%). Systematic assessment of relapses and response to relapse treatment may help clinicians to optimize outcomes for MS patients.

References

  1. J Neurol Neurosurg Psychiatry. 1987 May;50(5):511-6 - PubMed
  2. Cochrane Database Syst Rev. 2000;(4):CD001331 - PubMed
  3. Acta Neurol Scand. 2002 Mar;105(3):164-8 - PubMed
  4. Clin Ther. 2011 Oct;33(10):1413-32 - PubMed
  5. Neurology. 2009 Feb 17;72(7):602-8 - PubMed
  6. Brain. 2010 Jul;133(Pt 7):1900-13 - PubMed
  7. Patient. 2012;5(1):57-69 - PubMed
  8. Philos Trans R Soc Lond B Biol Sci. 1999 Oct 29;354(1390):1615-22 - PubMed
  9. Neurology. 1983 Nov;33(11):1444-52 - PubMed
  10. Postgrad Med J. 2005 May;81(955):302-8 - PubMed
  11. Int J MS Care. 2012 Fall;14(3):148-59 - PubMed
  12. Qual Life Res. 2012 Dec;21(10):1677-84 - PubMed
  13. Eur J Neurol. 2005 Dec;12(12):939-46 - PubMed
  14. Mult Scler. 2002 Oct;8(5):359-65 - PubMed

Publication Types